{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:12:34Z","timestamp":1776258754150,"version":"3.50.1"},"reference-count":13,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,3,24]]},"abstract":"<jats:p>\n            Cefiderocol is a newly approved siderophore cephalosporin that demonstrates expanded\n            <jats:italic>in vitro<\/jats:italic>\n            activity against multidrug-resistant Gram-negative bacteria. In two challenging cases reported here, cefiderocol shows potential utility as salvage therapy against difficult-to-treat pathogens with limited or no treatment options; however, two multicenter, randomized clinical trials have yielded mixed results among cefiderocol-treated patients. Taken together, clinicians must balance a clear need for cefiderocol in clinical practice with the uncertainties that have stemmed from the available data.\n          <\/jats:p>","DOI":"10.1128\/aac.00059-20","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T10:37:16Z","timestamp":1580294236000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":15,"title":["Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?"],"prefix":"10.1128","volume":"64","author":[{"given":"Ryan K.","family":"Shields","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"},{"name":"Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Fetroja (cefiderocol). Prescribing information","author":"Shionogi, Inc","year":"2019","unstructured":"Shionogi, Inc. 2019. Fetroja (cefiderocol). Prescribing information. Shionogi, Inc, Florham Park, NJ."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01872-19"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00948-19"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1159"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz827"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01968-17"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz318"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2334"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy963"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz828"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30554-1"},{"key":"e_1_3_3_13_2","volume-title":"Cefiderocol briefing document","author":"Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee","year":"2019","unstructured":"Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee. 2019. Cefiderocol briefing document. NDA 2094445. Shionogi, Inc, Florham Park, NJ."},{"key":"e_1_3_3_14_2","volume-title":"Efficacy and safety of cefiderocol versus high-dose meropenem in patients with nosocomial pneumonia\u2014results of a phase 3 randomized, multicenter, double-blind, non-inferiority study","author":"Wunderink RG","year":"2019","unstructured":"Wunderink RG, Matsunaga Y, Ariyasu M, Echols R, Menon A, Nagata TD. 2019. Efficacy and safety of cefiderocol versus high-dose meropenem in patients with nosocomial pneumonia\u2014results of a phase 3 randomized, multicenter, double-blind, non-inferiority study. Abstract LB4. IDWeek, Washington, DC."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00059-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00059-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:34:24Z","timestamp":1645486464000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00059-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,3,24]]}},"alternative-id":["10.1128\/AAC.00059-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.00059-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"assertion":[{"value":"2020-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00059-20"}}